SK bioscience
It is explained in two lines.
SK Bioscience is a company that was spun off from SK Chemicals in 2018.
As a company specializing in vaccines, it carries out from R&D of vaccines to consignment production and biosimilars (replicated drugs).
First of all, the vaccine market is trending upward like this.
It looks like it will soar from 2020 due to the corona issue.
Since it is expected that there will be a continuous epidemic of monkey pox in the future,
The rise won't stop
The fact that global warming has a causal relationship with the spread and mutation of infectious diseases.
It is unfortunate for mankind, but it is said that global warming is currently unstoppable and will reach a huge inflection point in 2050.
As it is already accelerating, abnormal climate + infectious diseases such as corona are also occurring.
After all, this industry is continuously growing and the prospects are good.
The most important thing in the bio industry is
R&D - Vaccine development, new drug development, etc.
CMO - Consignment production of vaccines
CDMO - CDO (Consignment Development) + CMO (Consignment Production) Consign vaccines or drugs from development to production
After all, CMO can be viewed as a foundry field in semiconductors.
It is said that Samsung Electronics is struggling to eat TSMC pie, and it is a net business with good sales and high profit margins.
Among them, in order to become a CMO, it is easy to enter the biosimilar (replicated drug) business.
SK Biopharm, a subsidiary of the same company, is focusing on biosimilars.
Through this synergy, SK Bioscience can expect performance from the CMO side.
The share of SK Bioscience's sales is about 15% from CDMO, 10% from the rest, and 70% from vaccine sales.
We are working hard to make a domestic corona virus.
Actually, there won't be much of an impact.
According to the data above, the field that SK Bioscience is thirsty for in 2022 is the corona vaccine.
A strategy to quickly commercialize it and spread it to developing countries to generate profits.
Currently, its own vaccine, GBP510, has also completed phase 3 clinical trials.
The government has already started purchasing, and there is a plan to export it in the second half of 2022.
The first quarter results and financials were not good.
Operating profit has dropped sharply, but it is said that CMO revenue is pushed back to the second half of the year.
So let's take a look at the chart.
If you look at the weekly candle, once last year's corona vaccine issue broke out, it continued to flow.
Well, it seems to be rebounding now in July.
If you look closely with a daily candle
The trading volume is continuously coming out, and it is slowly being prepared.
In the short term, the bottom seems to be around W110,000.
It is not easy to fall below that
Nevertheless, there is not much material that will surge in the short term.
Now, the corona virus has surpassed 100,000 again, and the fourth wave is expected to exceed 300,000.
This is a good thing here
These government-related issues can also act as issues.
To summarize briefly
The current outlook is not good. It takes time to become monetized. A company that just goes to the prospects
Vaccine R&D is still in its infancy (from 2018), so it is necessary to drive the share price up by showing results little by little.
Short term - It seems like it will take some time, but the purchase price is 110,000~120,000 won
long term - Selling corona vaccine to developing countries, it can go up while giving good news. The target is 21 million won.
